分析阿奇霉素序贯疗法治疗小儿支原体肺炎的临床安全性

Analyzing the Clinical Safety of Sequential Therapy with Azithromycin in the Treatment of Mycoplasma Pneumonia in Children

目的研究阿奇霉素序贯疗法应用于小儿支原体肺炎中的疗效。方法非随机选取苏州市吴中人民医院于2022年10月—2023年10月收治的90例小儿支原体肺炎患儿作为研究对象,并按照治疗方法不同分为对照组(头孢曲松治疗)和观察组(阿奇霉素序贯疗法),各45例。对比两组的治疗总有效率、不良反应发生率和体液免疫功能指标以及炎症因子。结果观察组治疗总有效率为97.78%(44/45),高于对照组的77.78%(35/45),差异有统计学意义(χ^(2)=8.389,P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。治疗后观察组体液免疫功能指标优于对照组,差异有统计学意义(P均<0.05)。治疗后观察组炎症因子水平低于对照组,差异有统计学意义(P均<0.05)。结论在治疗小儿支原体肺炎病程中给予阿奇霉素序贯疗法可以提高治愈率,改善预后情况。

Objective To investigate the therapeutic effect of sequential therapy with azithromycin in children with mycoplasma pneumonia.Methods A total of ninety children with mycoplasma pneumonia admitted to Wuzhong People's Hospital of Suzhou City from October 2022 to October 2023 were non-randomly selected as the study ob-jects,and were divided into control group(ceftriaxone treatment)and observation group(azithromycin sequential therapy)according to different treatment methods,forty-five cases in each group.The total effective rate,incidence of adverse reactions,humoral immune function indexes and inflammatory factors were compared between the two groups.Results The total effective rate of the observation group was 97.78%(44/45),which was higher than 77.78%(35/45)of the control group,the difference was statistically significant(χ^(2)=8.389,P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).After treatment,the humoral immune function indexes of the observation group were better than those of the control group,and the differences were statistically significant(all P<0.05).After treatment,the levels of inflammatory factors in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion Sequential therapy with azithromycin can improve the cure rate and prognosis in the treatment of pediatric mycoplasma pneumonia.